Shattuck Labs, Inc. (NASDAQ:STTK) Given Consensus Rating of “Moderate Buy” by Brokerages

Shattuck Labs, Inc. (NASDAQ:STTK) has been given a consensus rating of “Moderate Buy” by the six analysts that are currently covering the company, Marketbeat reports. Three research analysts have rated the stock with a hold recommendation, one has given a buy recommendation and two have given a strong buy recommendation to the company. The average 1-year price target among brokers that have covered the stock in the last year is $7.00.

Several research firms have commented on STTK. Needham & Company LLC reaffirmed a “hold” rating on shares of Shattuck Labs in a report on Thursday, August 14th. Leerink Partners dropped their price target on shares of Shattuck Labs from $4.00 to $2.00 and set an “outperform” rating for the company in a research note on Thursday, August 14th.

Shattuck Labs Trading Down 1.9%

Shares of NASDAQ STTK opened at $1.01 on Thursday. Shattuck Labs has a one year low of $0.6922 and a one year high of $3.95. The firm has a market capitalization of $48.38 million, a PE ratio of -0.83 and a beta of 1.63. The business has a 50-day moving average price of $0.87 and a two-hundred day moving average price of $1.01.

Shattuck Labs (NASDAQ:STTK) last released its quarterly earnings data on Thursday, August 14th. The company reported ($0.24) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.01. Research analysts anticipate that Shattuck Labs will post -1.48 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in STTK. Prosight Management LP boosted its holdings in Shattuck Labs by 15.1% during the fourth quarter. Prosight Management LP now owns 6,638,935 shares of the company’s stock worth $8,033,000 after purchasing an additional 873,409 shares during the last quarter. Adage Capital Partners GP L.L.C. lifted its stake in Shattuck Labs by 61.2% in the fourth quarter. Adage Capital Partners GP L.L.C. now owns 4,675,000 shares of the company’s stock valued at $5,657,000 after acquiring an additional 1,775,000 shares during the last quarter. Pinnacle Associates Ltd. lifted its stake in Shattuck Labs by 4.9% in the second quarter. Pinnacle Associates Ltd. now owns 1,363,723 shares of the company’s stock valued at $1,080,000 after acquiring an additional 64,000 shares during the last quarter. 683 Capital Management LLC lifted its stake in Shattuck Labs by 4.3% in the second quarter. 683 Capital Management LLC now owns 1,095,000 shares of the company’s stock valued at $867,000 after acquiring an additional 45,000 shares during the last quarter. Finally, Northern Trust Corp lifted its stake in Shattuck Labs by 9.2% in the fourth quarter. Northern Trust Corp now owns 353,616 shares of the company’s stock valued at $428,000 after acquiring an additional 29,870 shares during the last quarter. Institutional investors and hedge funds own 58.74% of the company’s stock.

About Shattuck Labs

Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.